The Food and Drug Administration approved Doribax as a new treatment for complicated intra-abdominal and complicated urinary tract infections, including pyelonephritis. Johnson & Johnson (JNJ) said Doribax demonstrated activity against a wide range of gram-positive and gram-negative bacteria -- including Pseudomonas -- that cause serious infections. Doribax belongs to a class of antibacterial agents called carbapenems, which are important for treating serious infections caused by bacteria.
|